ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LEGN Legend Biotech Corporation

42.98
0.38 (0.89%)
Pre Market
Last Updated: 07:03:24
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Legend Biotech Corporation LEGN NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.38 0.89% 42.98 07:03:24
Open Price Low Price High Price Close Price Previous Close
42.60
more quote information »

Recent News

Date Time Source Heading
5/13/202406:10IHMARKETNEWSU.S. Futures Climb Amid High Expectations for Inflation..
5/13/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/13/202406:00BWLegend Biotech Reports First Quarter 2024 Results and Recent..
4/22/202412:05BWCARVYKTI® (ciltacabtagene autoleucel) Approved by the..
4/11/202407:00BWLegend Biotech to Host Investor Conference Call on First..
4/05/202422:30BWLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel)..
3/19/202407:30BWLegend Biotech Announces Publication of Inaugural..
3/15/202414:15BWCARVYKTI® (ciltacabtagene autoleucel) Receives..
3/11/202406:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
3/11/202406:00BWLegend Biotech Reports Fourth Quarter and Full Year 2023..
3/11/202405:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
2/28/202417:46EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
2/27/202418:47EDGAR2Form 144 - Report of proposed sale of securities
2/23/202412:10EDGAR2Form 144 - Report of proposed sale of securities
2/23/202406:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/23/202406:15BWLegend Biotech Announces Positive CHMP Opinion for CARVYKTI®..
2/14/202419:34EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202407:00BWLegend Biotech to Host Investor Conference Call on Fourth..
1/23/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/23/202406:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/09/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/03/202410:28BWLegend Biotech Announces Closing of License Transaction for..
1/03/202407:30BWLegend Biotech Announces Closing of License Transaction for..
1/02/202407:30BWLegend Biotech to Participate in the 42nd Annual J.P. Morgan..
12/27/202309:00EDGAR2Form 144 - Report of proposed sale of securities
12/22/202314:38EDGAR2Form 144 - Report of proposed sale of securities
12/22/202314:21EDGAR2Form 144 - Report of proposed sale of securities
12/21/202316:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/21/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202313:31EDGAR2Form 144 - Report of proposed sale of securities
12/11/202318:30BWPatient-Reported Outcomes from the CARTITUDE-4 Study Showed..
11/20/202305:25IHMARKETNEWSMonday’s Wall Street Highlights: GM, Microsoft, Citigroup,..
11/20/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/20/202305:00BWLegend Biotech Reports Third Quarter 2023 Results and Recent..
11/13/202308:16DJNLegend Biotech Subsidiary in License Agreement With Novartis
11/13/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/13/202307:30BWLegend Biotech Announces Exclusive, Global License Agreement..
11/07/202307:30BWLegend Biotech to Host Investor Conference Call on..
11/02/202308:17BWLegend Biotech to Showcase Leadership in Multiple Myeloma..
10/17/202316:39EDGAR2Form 144 - Report of proposed sale of securities
10/17/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/16/202316:20EDGAR2Form 144 - Report of proposed sale of securities
9/27/202311:02EDGAR2Form 144 - Report of proposed sale of securities
9/25/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/22/202315:20EDGAR2Form 144 - Report of proposed sale of securities
9/22/202315:10EDGAR2Form 144 - Report of proposed sale of securities
9/18/202315:41EDGAR2Form 144 - Report of proposed sale of securities
8/28/202309:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/21/202315:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/15/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..